FGF17 dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
FGF17 is the factor found when young spinal fluid was pumped into the brains of old mice. In people it is known for something else entirely: faults in the FGF17 gene stop puberty from starting.
Evidence grade for FGF17: Preliminary. The rule: studied in people, but no published study has had people take it. The sum on this page: 1 human study where nobody was given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 0
- Found nothing
- 0
Dose
No human dose established
No published study on this page has given this compound to people and reported a result.
1 human study where nobody was given it
4 effects reported, 4 unwanted, by people using it, not a trial
Goal pages: Brain, memory and mood, Ageing and longevity, Heart and circulation
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
This is a growth factor found in spinal fluid. In old mice, pumping it straight into the brain improved memory. In people it is known for something else. Faults in its gene stop puberty from starting.
What people take it for
- Memory and brain repair.
- Rebuilding the insulating sheath around nerve fibres.
What studies in people showed
Nobody has been given this, and no trial is registered. The human record is genetics. Researchers sequenced genes in 386 people whose puberty never started and 155 people without that problem. Some of those affected carried faults in this gene. That says losing it while the body is built causes a reproductive and smell disorder. It says nothing about giving it to an older adult. In mice, pumping young spinal fluid into old brains improved memory. The cells that responded most make the insulating sheath around nerve fibres. Pumping in this factor alone did the same job. Blocking it harmed memory in young mice.
What people report
Reports, not study results
The good
- We have not collected user reports on this one yet.
The bad
- The mouse work pumped it straight into the brain. You cannot do that long term in a person.
- There is no safety data, no dosing data and no trial.
- Pumping a growth factor into a brain raises questions about cells growing when they should not.
- The good human genetics on this gene is about puberty, and gets misread as support for the ageing idea.
Where these come from: The genetics study and the mouse results come from the studies on this page. No user reports exist.
My bottom line
Striking in mice, delivered in a way no person can use, and its human file is about something else entirely.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Animal and lab work, not yet tested in people
Real results, but from animals or cells, not people. What works in a mouse often does not work the same way in a person. Nobody can patent this, so nobody would ever earn back the cost of a study in people. That is usually why there is none. The record on this one is set out below.
- Memory and thinking1 animal or lab study
- Heart attacks and strokes1 animal or lab study
- Living longer1 animal or lab study
33 of the 36 indexed goals have no study of any kind behind FGF17
No study in people, animals or cells on this page reports a result for these. That does not prove FGF17 does nothing for them. It does mean anything you have heard about FGF17 and one of these did not come from a study cited here.
Show full evidence
What is FGF17?
FGF17 is the factor found when young spinal fluid was pumped into the brains of old mice. In people it is known for something else entirely: faults in the FGF17 gene stop puberty from starting.
Nobody has been given FGF17. There is no registered trial.
The human record for FGF17 is real and solid, and it is about something else. In 2013, researchers sequenced genes in 386 unrelated people whose puberty never started because of a hormone problem present from birth, plus 155 people without it. Some of those affected carried faults in FGF17, alongside faults in four other genes in the same signalling group. That condition, and the version of it that also takes away the sense of smell, are problems with how a particular set of hormone nerve cells develops. That is good quality human FGF17 data. It says that losing FGF17 while the body is being built causes a reproductive and smell disorder. It says nothing about giving FGF17 to an older adult.
A 2022 Nature paper came at the young blood question from a different angle. It asked about spinal fluid rather than blood plasma, since spinal fluid is what brain cells actually sit in. Pumping young spinal fluid straight into the brains of old mice improved their memory. Looking at gene activity in the memory centre, the cells that responded most were the ones that make the insulating sheath around nerve fibres. Young spinal fluid made their parent cells divide and mature, both in the ageing brain and in a dish. Tracking freshly made genetic messages pointed at one control protein as the go-between. Screening spinal fluid for things that switch that protein on found FGF17. Pumping in FGF17 on its own was enough to make those parent cells divide and to lock in long-term memories in old mice. Blocking it harmed memory in young mice.
A 2026 Neurotherapeutics paper reported that FGF17 both kept nerve cells alive and rebuilt that insulating sheath, restoring what was lost after a stroke. That was again in animals.
How does FGF17 work?
In mice, young spinal fluid makes the parent cells of the brain's insulating sheath divide and mature in the ageing memory centre. It does this through a control protein whose levels fall with age in those cells. FGF17 was found by screening spinal fluid for things that switch that protein on. Pumping in FGF17 alone made those cells divide and locked in long-term memories in old mice. Blocking it harmed memory in young mice. In people, the known biology is about development. FGF17 is part of a signalling group that shapes the boundary between the middle and hind brain and the front of the brain. Faults that stop it working cause a hormone condition where puberty never starts. Nothing links the mouse memory work to an outcome in a person.
What have studies in people found about FGF17?
Nobody has been given FGF17. The human evidence is genetic. Faults in FGF17 have been found in people whose puberty never started because of a hormone problem present from birth, a condition that also affects smell. That is real human FGF17 data, and it is not about ageing.
- American Journal of Human Genetics 2013: 386 unrelated people whose puberty never started, plus 155 people without the condition, were sequenced across seven candidate genes. Faults in FGF17 were found among those affected, alongside faults in four other genes in the same group.
- No study has given FGF17 to a person, for anything, and no trial is registered.
- There is no data at all in people on safety, dosing or how the body handles FGF17.
What this does not tell you: Genetic evidence that losing FGF17 during development causes a disorder does not tell you what giving FGF17 to an adult would do. It can easily mislead in either direction. The mouse ageing work also pumped FGF17 straight into the brain, through the spinal fluid. That is not a route you could use for a long-term treatment in a person. And pumping a growth factor into the brain raises questions about cells growing when they should not, which a memory study in old mice is not built to answer.
The state of the research
FGF17 is the clearest example in this batch of a factor whose human record exists, is good, and is about something else. Search for FGF17 in people and you will find the genetics of a condition where puberty never starts. That is a careful study in 386 affected people, and it would be easy to read it as human proof of an ageing target. It is not. It is evidence that FGF17 matters while the brain's hormone and smell systems are being built.
Getting it where it needs to go is the other honest obstacle. The 2022 experiment pumped young spinal fluid, and then FGF17, straight into the brain. A protein given into the body that then has to reach the memory centre is a completely different problem, and nobody has worked on it. That is why the field has no registered trial. It is not a reason to think the biology is wrong.
The 2026 stroke paper is worth noting. It is the first time this finding has been pushed into an injury model, where what counts as success is clearer than in ordinary memory decline. It is still animal work.
The evidence, in charts
Fig. 1a · how many people
386people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| American Journal of Human Genetics 2013 | 386 | 100% |
The whole total is one study of 386. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
1 of 4 sources here is a study in people. The rest are not.
- Study in people · done in people125%
- Animal study · done in animals250%
- Review of studies · sums up other studies125%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 4 different years, 2013 to 2026, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Biologic
- Molecule weight
- Not on file
- Half-life
- None on file
- Chain length
- None on file
No amino acid sequence is on file for FGF17, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2013Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism
Almost everything known about FGF17 in people comes from a genetics study, and it is about puberty, not ageing. Researchers sequenced seven genes in 386 people with a condition that stops puberty starting, including the form that also removes the sense of smell, plus 155 people without it. Three of them carried FGF17 mutations. Most of those mutations damaged how the protein works in laboratory tests. Losing FGF17 during development causes a reproductive and smell disorder. Nobody was given the protein.
Human genetics, and the main body of FGF17 data in people. Seven candidate genes in the FGF8 signalling group were sequenced in 386 unrelated individuals with congenital hypogonadotropic hypogonadism, including its anosmia-associated form Kallmann syndrome, and 155 controls. Mutations in FGF17 were identified among the affected individuals. Loss of FGF17 function during development causes a reproductive and olfactory disorder; this is not an ageing study.
- Review of studies2024Fgf17: A regulator of the mid/hind brain boundary in mammals
A review of what FGF17 does in mammals, focused on its job while the brain is being built, shaping the boundary between the middle and hind brain. That is the setting this factor was studied in for twenty years before the ageing work.
Review of FGF17 biology in mammals, focused on its developmental role in patterning the mid-hindbrain boundary, which is the context in which this factor was studied for two decades before the ageing work.
- Animal study2022Young CSF restores oligodendrogenesis and memory in aged mice via Fgf17
In mice, pumping young spinal fluid into old brains improved memory. The cells that responded most were the ones that make the insulating sheath around nerve fibres. Young spinal fluid made their parent cells divide and mature, both in the ageing memory centre and in a dish, through one control protein. Pumping in FGF17 on its own was enough to make those cells divide and to lock in long-term memories in old mice. Blocking FGF17 harmed memory in young mice.
Mouse. Infusing young cerebrospinal fluid into aged brains improved memory. Oligodendrocytes were the most responsive cell type, and young CSF boosted oligodendrocyte progenitor proliferation and differentiation in the aged hippocampus and in culture, mediated by serum response factor. FGF17 infusion alone was sufficient to induce progenitor proliferation and long-term memory consolidation in aged mice, and FGF17 blockade impaired cognition in young mice.
- Animal study2026FGF17 synergistically targets neuronal survival and oligodendrogenesis to restore stroke deficits
In animals, FGF17 both kept nerve cells alive and rebuilt the insulating sheath around nerve fibres, restoring what was lost after a stroke. That pushes the finding past normal ageing and into injury.
Animal. FGF17 acted on neuronal survival and oligodendrogenesis together to restore deficits in a stroke model, extending the oligodendrocyte finding beyond normal ageing into injury.
Common questions
Has FGF17 been tested in people?
Not in a completed trial cited here. 1 human study where nobody was given it. FGF17 is the factor found when young spinal fluid was pumped into the brains of old mice. In people it is known for something else entirely: faults in the FGF17 gene stop puberty from starting.
What is the FGF17 dosage?
No human dose established. No published study on this page has given this compound to people and reported a result. 1 human study where nobody was given it
Is FGF17 FDA-approved?
Not approved, and never given to a person. We could not find a registered study of FGF17 for any use.
Has FGF17 been given to a human?
No. Nobody has been given FGF17 for anything. There is no safety data and no registered trial. The mouse work pumped it straight into the brain.
What did young cerebrospinal fluid do in mice?
Pumping young spinal fluid into the brains of old mice improved their memory. The cells that responded most were the ones that make the insulating sheath around nerve fibres. FGF17 was the factor that did it on its own. Pumping it in made those cells' parent cells divide and locked in long-term memories in old mice. Blocking it harmed memory in young mice.
Is FGF17 linked to any human condition?
Yes, but not to ageing. Faults in FGF17 have been found in people whose puberty never started because of a hormone problem present from birth, including the version that also takes away the sense of smell. That came from a study of 386 affected people. It is a condition of how the body develops, affecting reproduction and smell.